These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 19703268)
1. Adaptive designs for Phase I dose-finding studies. Zhou Y Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268 [TBL] [Abstract][Full Text] [Related]
2. Choice of designs and doses for early phase trials. Zhou Y Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290 [TBL] [Abstract][Full Text] [Related]
3. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity. Wang M; Day R J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253 [TBL] [Abstract][Full Text] [Related]
4. An optimization algorithm for designing phase I cancer clinical trials. Jiang H; Liu Y; Su Z Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867 [TBL] [Abstract][Full Text] [Related]
5. Dose-finding in phase I clinical trials based on toxicity probability intervals. Ji Y; Li Y; Nebiyou Bekele B Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248 [TBL] [Abstract][Full Text] [Related]
6. Phase I trials: from traditional to newer approaches part II. Macaluso M; Krams M; Preskorn SH J Psychiatr Pract; 2011 Jul; 17(4):277-84. PubMed ID: 21775829 [TBL] [Abstract][Full Text] [Related]
7. Multiple-objective designs in a dose-response experiment. Zhu W; Wong WK J Biopharm Stat; 2000 Feb; 10(1):1-14. PubMed ID: 10709797 [TBL] [Abstract][Full Text] [Related]
8. Optimal designs for estimating the most successful dose. Zohar S; O'Quigley J Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893 [TBL] [Abstract][Full Text] [Related]
9. Commentary on 'Designs of dose-escalation trials with quantitative responses'. Haines LM Stat Med; 2009 Dec; 28(30):3742-4; discussion 3759-60. PubMed ID: 19967751 [No Abstract] [Full Text] [Related]
10. Commentary on 'Designs for dose-escalation trials with quantitative responses'. Atkinson AC Stat Med; 2009 Dec; 28(30):3739-41; discussion 3759-60. PubMed ID: 19967753 [No Abstract] [Full Text] [Related]
11. Improved up-and-down designs for phase I trials. Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752 [TBL] [Abstract][Full Text] [Related]
12. Implementation of a Bayesian design in a dose-escalation study of an experimental agent in healthy volunteers. Zhou Y; Whitehead J; Korhonen P; Mustonen M Biometrics; 2008 Mar; 64(1):299-308. PubMed ID: 17608785 [TBL] [Abstract][Full Text] [Related]
14. An adaptive dose-finding design incorporating both toxicity and efficacy. Zhang W; Sargent DJ; Mandrekar S Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478 [TBL] [Abstract][Full Text] [Related]
15. A Bayesian dose finding design for dual endpoint phase I trials. Loke YC; Tan SB; Cai Y; Machin D Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039 [TBL] [Abstract][Full Text] [Related]
16. A hybrid Bayesian adaptive design for dose response trials. Chang M; Chow SC J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172 [TBL] [Abstract][Full Text] [Related]
17. Statistical designs for early phases of cancer clinical trials. Guan S J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011 [TBL] [Abstract][Full Text] [Related]
18. Two-dimensional dose finding in discrete dose space. Wang K; Ivanova A Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096 [TBL] [Abstract][Full Text] [Related]
19. Commentary on 'Designs for dose-escalation trials with quantitative responses'. O'Quigley J Stat Med; 2009 Dec; 28(30):3745-50; discussion 3759-60. PubMed ID: 19967752 [TBL] [Abstract][Full Text] [Related]
20. Optimal phase I dose-escalation trial designs in oncology--a simulation study. Gerke O; Siedentop H Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]